Study Reveals Devastating Consequences of Stopping Popular Weight Loss Medication Mounjaro
A recent study has shed light on the alarming consequences of stopping the weight loss medication Mounjaro, revealing that individuals who discontinue use not only regain weight but also experience a reversal in other vital health improvements.
Mounjaro, containing the active ingredient tirzepatide, has become a go-to treatment for obesity and related conditions, with studies demonstrating remarkable weight loss results. However, researchers have now found that when users stop taking Mounjaro, they experience an unfortunate rebound effect, leading to significant weight regain and a reversal of other beneficial health changes.
According to the study published in the journal Jama Internal Medicine, participants who received Mounjaro alongside diet and exercise support for 36 weeks, followed by a 52-week placebo period, showed alarming results. By the end of the year-long trial, an astonishing 82% had regained at least 25% of their weight loss. Furthermore, those with greater weight regain experienced more pronounced reversals in measures such as waist circumference, "bad" cholesterol levels, blood pressure, and blood glucose levels.
Experts warn that these findings highlight the critical importance of sustained weight management through lifestyle intervention and obesity medications to maintain long-term cardiometabolic benefits. As Professor Naveed Sattar aptly put it, "the findings are not a surprise, as excess weight is a well-established driver of elevated blood pressure and impaired glucose control."
The study's results also underscore the potential risks associated with stopping weight loss medications like Mounjaro, particularly for individuals with pre-existing heart conditions. According to Sattar, discontinuing these medications could "remove a protective effect," increasing the risk of hospitalization for heart failure or death from any cause.
While experts caution that more research is needed, the study's findings serve as a sobering reminder of the complexities involved in managing obesity and related health conditions. As Jane Ogden, an expert in health sciences, noted, "taking weight-loss jabs does not always create healthier eating and exercise habits, often leading to poorer diets as people lose motivation to eat well."
A recent study has shed light on the alarming consequences of stopping the weight loss medication Mounjaro, revealing that individuals who discontinue use not only regain weight but also experience a reversal in other vital health improvements.
Mounjaro, containing the active ingredient tirzepatide, has become a go-to treatment for obesity and related conditions, with studies demonstrating remarkable weight loss results. However, researchers have now found that when users stop taking Mounjaro, they experience an unfortunate rebound effect, leading to significant weight regain and a reversal of other beneficial health changes.
According to the study published in the journal Jama Internal Medicine, participants who received Mounjaro alongside diet and exercise support for 36 weeks, followed by a 52-week placebo period, showed alarming results. By the end of the year-long trial, an astonishing 82% had regained at least 25% of their weight loss. Furthermore, those with greater weight regain experienced more pronounced reversals in measures such as waist circumference, "bad" cholesterol levels, blood pressure, and blood glucose levels.
Experts warn that these findings highlight the critical importance of sustained weight management through lifestyle intervention and obesity medications to maintain long-term cardiometabolic benefits. As Professor Naveed Sattar aptly put it, "the findings are not a surprise, as excess weight is a well-established driver of elevated blood pressure and impaired glucose control."
The study's results also underscore the potential risks associated with stopping weight loss medications like Mounjaro, particularly for individuals with pre-existing heart conditions. According to Sattar, discontinuing these medications could "remove a protective effect," increasing the risk of hospitalization for heart failure or death from any cause.
While experts caution that more research is needed, the study's findings serve as a sobering reminder of the complexities involved in managing obesity and related health conditions. As Jane Ogden, an expert in health sciences, noted, "taking weight-loss jabs does not always create healthier eating and exercise habits, often leading to poorer diets as people lose motivation to eat well."